Elsevier and the Society of Hospital Medicine announce joint initiative aimed at helping patients with underlying substance use disorders

Elsevier, a global leader in evidence-based clinical practice content, research publishing and information analytics, today announced that it will partner with the Society of Hospital Medicine (SHM) in the development of materials to help hospitalists at the point-of-care with the identification, inpatient management, and discharge planning of patients with underlying substance use disorders (SUD). More than 17 million U.S. adults are affected by SUD and its underlying health conditions.

As part of this initiative, Elsevier has provided grant support to enable the Society of Hospital Medicine to develop a suite of tools and resources for hospitalists that will help them in identifying patients with SUD, initiating medications for opioid use disorder (MOUD) in the hospital setting, and supporting patient discharge to the home or community. Faculty working on the project have access to evidence-based information through Elsevier’s ClinicalKey® to inform their research. At project completion, SHM will contribute to the creation of point-of-care recommendations on the topic within ClinicalKey, allowing ClinicalKey users to quickly access the information, while reinforcing best practices recommended by SHM.

“Hospitalization represents an important step in identifying and treating patients with SUD,” said Josh Schoeller, President, Clinical Solutions, Elsevier. “It’s imperative to support hospitalists in acquiring the knowledge, evidence-based strategies and tools to effectively manage this patient population and address the growing health crisis in our country.”

The first output of this project, due to release this year, will be a discussion guide to support hospitalists in conducting patient-centered discussions with individuals who have a diagnosis of SUD with a focus on Opioid Use Disorder (OUD) including best practices and clinical scenarios in a case study format which review how to identify patients with OUD, initiate treatment and facilitate effective transitions of care strategies.

“We’re pleased to collaborate with Elsevier on this important initiative that we believe will have an impact in the health and wellbeing of many Americans suffering from substance use disorders,” said Jenna Goldstein, Director of SHM’s Center for Quality Improvement.

---

Notes for editors

About the Society of Hospital Medicine

Representing the fastest growing specialty in modern healthcare, the Society of Hospital Medicine (SHM) is celebrating 25 years as the leading medical society for hospitalists and their patients. SHM is dedicated to promoting the highest quality care for all hospitalized patients and overall excellence in the practice of hospital medicine through quality improvement, education, advocacy, and research. Over the past decade, studies have shown that hospitalists can contribute to decreased patient lengths of stay, reductions in hospital costs and readmission rates, and increased patient satisfaction. For more information about SHM and hospital medicine, visit hospitalmedicine.org 新しいタブ／ウィンドウで開く.

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。